Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Single-arm, Open-label, Single/Multiple-dose Escalation, and Cohort Expansion Phase Ia/Ib Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Oral CSCJC3456 Tablets in Patients With Advanced Malignant Solid Tumors
This study is a multicenter, open phase I clinical study of dose escalation, cohort expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary efficacy of CSCJC3456 in patients with advanced malignant solid tumors.
/ CompletedNot Applicable 评价健康受试者皮下注射CJC-1134-PC注射液分别与二甲双胍、阿托伐他汀、华法林药物-药物相互作用的临床研究
[Translation] Clinical study to evaluate the drug-drug interactions of subcutaneous CJC-1134-PC injection with metformin, atorvastatin, and warfarin in healthy subjects
主要目的:评价在健康受试者中皮下注射CJC-1134-PC注射液分别对二甲双胍、阿托伐他汀、华法林的药代动力学的影响,为CJC-1134-PC注射液临床合并用药提供科学依据。 次要目的:1、评价在健康受试者中皮下注射CJC-1134-PC注射液对华法林的药效学的影响;2、评价在健康受试者中皮下注射CJC-1134-PC注射液分别与二甲双胍、阿托伐他汀、华法林联合给药的安全性。
[Translation] Primary objective: To evaluate the effect of subcutaneous injection of CJC-1134-PC injection on the pharmacokinetics of metformin, atorvastatin, and warfarin in healthy subjects, and to provide a scientific basis for the clinical combination of CJC-1134-PC injection. Secondary objectives: 1. To evaluate the effect of subcutaneous injection of CJC-1134-PC injection on the pharmacodynamics of warfarin in healthy subjects; 2. To evaluate the safety of subcutaneous injection of CJC-1134-PC injection in combination with metformin, atorvastatin, and warfarin in healthy subjects.
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Designed to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once A Week in Patients With Type 2 Diabetes With Inadequately Controlled Blood Glucose Level After Metformin Monotherapy or Metformin in Combination With Insulin Secretagogues
This study is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Trial Designed to Evaluate the Efficacy and Safety of CJC-1134-PC Injection Administered Once A Week in Patients with Type 2 Diabetes with Inadequately Controlled Blood Glucose Level after Metformin Monotherapy or Metformin in Combination with Insulin Secretagogues.
100 Clinical Results associated with Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
0 Patents (Medical) associated with Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
100 Deals associated with Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.
100 Translational Medicine associated with Changshan ConjuChem BioPharmaceutical Research and Development (Hebei) Co., Ltd.